Olmesartan Medoxomil E Amlodipina Zentiva (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil E Amlodipina Zentiva, is an ARB presented as a tablet for oral use. It treats hypertension, often in combination with other antihypertensive agents, and is intended for adult patients. GNH USA supplies Olmesartan Medoxomil E Amlodipina Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Medoxomil E Amlodipina Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals pharmacies and clinics worldwide.

Olmesartan medoxil/amlodipine is an antihypertensive combination that acts on the renin‑angiotensin system and calcium‑channel pathways to lower blood pressure. - Hypertension: helps achieve target blood pressure when monotherapy is insufficient. - Hypertension with isolated systolic hypertension in the elderly: provides additional systolic control. - Hypertension in patients with metabolic syndrome: contributes to overall cardiovascular risk reduction.

Adverse reactions may occur with any antihypertensive therapy and should be monitored.

Common Side Effects: - Dizziness - Headache - Peripheral edema - Flushing - Fatigue - Nausea

Serious or Rare Side Effects: - Angio‑edema - Severe hypotension - Acute kidney injury - Hepatic dysfunction - Heart block - Hyperkalemia

When prescribing Olmesartan Medoxil E Amlodipina Zentiva, clinicians should consider several safety aspects. - Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium and sodium levels, especially if combined with diuretics. - Pregnancy: avoid use during pregnancy due to risk of fetal toxicity. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Drug interactions: review concomitant medications for additive blood‑pressure effects. - Store at below  : keep the ...